Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Osteoporosis: the emperor has no clothes.

Järvinen TL, Michaëlsson K, Aspenberg P, Sievänen H.

J Intern Med. 2015 Jun;277(6):662-73. doi: 10.1111/joim.12366. Review.

2.

Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study.

Erviti J, Alonso A, Gorricho J, López A.

BMJ Open. 2013 Feb 20;3(2). pii: e002084. doi: 10.1136/bmjopen-2012-002084. Print 2013.

3.

A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study.

Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH.

PLoS One. 2012;7(12):e53032. doi: 10.1371/journal.pone.0053032. Epub 2012 Dec 31.

4.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.

5.

Effects of D-003 (10 mg/day) on bone mineral density of the lumbar spine and femoral neck in postmenopausal women: a randomized, double-blinded study.

Ceballos A, Castaño G, Mendoza S, González J, Mas R, Fernández L, Illnait J, Mesa M, Gámez R, Fernández JC, Telles R, Marrero D, Eng MG, Ruiz D, Jardines Y.

Korean J Intern Med. 2011 Jun;26(2):168-78. doi: 10.3904/kjim.2011.26.2.168. Epub 2011 Jun 1.

6.

Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate.

Eslami B, Zhou S, Van Eekeren I, LeBoff MS, Glowacki J.

Calcif Tissue Int. 2011 Apr;88(4):272-80. doi: 10.1007/s00223-011-9473-5. Epub 2011 Feb 15.

7.

Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges.

Jain N, Weinstein RS.

Nat Rev Rheumatol. 2009 Jun;5(6):341-6. doi: 10.1038/nrrheum.2009.87. Review.

8.

Giant osteoclast formation and long-term oral bisphosphonate therapy.

Weinstein RS, Roberson PK, Manolagas SC.

N Engl J Med. 2009 Jan 1;360(1):53-62. doi: 10.1056/NEJMoa0802633.

9.

Alendronate sodium in the management of osteoporosis.

Prinsloo PJ, Hosking DJ.

Ther Clin Risk Manag. 2006 Sep;2(3):235-49.

11.

Medical treatment of vertebral osteoporosis.

Lippuner K.

Eur Spine J. 2003 Oct;12 Suppl 2:S132-41. Epub 2003 Sep 17. Review.

12.

Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.

Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC.

J Clin Invest. 2002 Apr;109(8):1041-8.

13.
14.

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ.

J Clin Invest. 1997 Sep 15;100(6):1475-80.

Supplemental Content

Support Center